123 related articles for article (PubMed ID: 12717923)
1. [Radiologic diagnosis of bone metastases recurrence in patients with prostate cancer treated strontium-89].
Barysheva EV; Selivanov SP; Riannel' IuE; Velichko SA; Usynin EA; Usov VIu
Vestn Rentgenol Radiol; 1999; (5):32-6. PubMed ID: 12717923
[TBL] [Abstract][Full Text] [Related]
2. [Radiologic follow-up and prognosis of efficiency of systemic Sr-89 Cl-2 therapy of bone metastases in prostate cancer].
Barysheva EV; Obradovic V; Stefanovic L; Riannel' IuE; Regoe S; Selivanov SP; Artiko V; Isaeva SN; Velichko SA; Tuzikov SA; Ussov VIu
Vestn Rentgenol Radiol; 2000; (6):46-50. PubMed ID: 12717912
[TBL] [Abstract][Full Text] [Related]
3. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases.
Kasalický J; Krajská V
Eur J Nucl Med; 1998 Oct; 25(10):1362-7. PubMed ID: 9818274
[TBL] [Abstract][Full Text] [Related]
4. [New criteria for scintigraphic follow-up of bone metastases following radiotherapy. Results of functional scintigraphy using 99mTc-MDP].
Knop J; Stritzke P; Langendorff G
Nuklearmedizin; 1985 Dec; 24(5-6):238-43. PubMed ID: 4094901
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
Zhao W; Deng H; Jie P; Qing C; Zhang X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
[TBL] [Abstract][Full Text] [Related]
6. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
Blake GM; Zivanovic MA; Blaquiere RM; Fine DR; McEwan AJ; Ackery DM
J Nucl Med; 1988 Apr; 29(4):549-57. PubMed ID: 3351609
[TBL] [Abstract][Full Text] [Related]
7. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
[TBL] [Abstract][Full Text] [Related]
8. Prediction of tumor absorbed dose by Tc-99m-MDP scintigraphy prior to treatment with Sr-89.
Manetou A; Limourls GS
Anticancer Res; 1997; 17(3B):1845-7. PubMed ID: 9179243
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of stage 4 neuroblastoma patients by means of MIBG and 99mTc-MDP scintigraphy.
Turba E; Fagioli G; Mancini AF; Rosito P; Galli A; Alvisi P
J Nucl Biol Med (1991); 1993 Sep; 37(3):107-14. PubMed ID: 8218456
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
11. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
12. [Patterns of bone metastases of carcinoma of the prostate: evaluation using 99mTC-MDP bone scintigraphy].
Matsuda H; Sakashita S; Arakawa M; Koyanagi T
Nihon Hinyokika Gakkai Zasshi; 1987 Oct; 78(10):1809-13. PubMed ID: 3444173
[No Abstract] [Full Text] [Related]
13. [Clinical usefulness of 123I-IMP scintigraphy in the diagnosis of bone metastases from hepatocellular carcinoma: comparison with 99mTc-MDP bone scintigraphy].
Suto Y; Tanigawa N; Iwamiya T; Kato T; Endo K; Shabana M; Ohta Y
Nihon Igaku Hoshasen Gakkai Zasshi; 1993 Aug; 53(8):953-9. PubMed ID: 8396760
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenetic differentiation of the bone superscan using bone marrow scintigraphy].
Weckesser M; Müller-Mattheis VG; Vosberg H; Müller-Gärtner HW
Nuklearmedizin; 1998 Jun; 37(4):156-8. PubMed ID: 9650218
[TBL] [Abstract][Full Text] [Related]
15. Quantitative bone scintigraphy and 24-hour whole-body counting of 99mTc-methylene diphosphonate in patients with prostatic carcinoma.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Nuklearmedizin; 1992 Oct; 31(5):178-81. PubMed ID: 1465355
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of 99mTc-PMT whole body scans in the diagnosis of bone metastases from hepatocellular carcinoma].
Nakanishi Y; Ha-Kawa SK
Nihon Igaku Hoshasen Gakkai Zasshi; 1992 Feb; 52(2):208-16. PubMed ID: 1313962
[TBL] [Abstract][Full Text] [Related]
17. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone.
Porter AT
Eur Urol; 1994; 26 Suppl 1():20-5. PubMed ID: 7537665
[TBL] [Abstract][Full Text] [Related]
18. [The place of 99mTc-MDP skeletal scintigraphy in neuroblastoma. Is a new assessment necessary?].
Sautter-Bihl ML; Bihl H; Heinze HG
Nuklearmedizin; 1991 Feb; 30(1):7-12. PubMed ID: 2062676
[TBL] [Abstract][Full Text] [Related]
19. Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up.
Kloiber R; Molnar CP; Barnes M
Radiology; 1987 Jun; 163(3):719-23. PubMed ID: 3575721
[TBL] [Abstract][Full Text] [Related]
20. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
